United-Guardian, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023, compared with FY2022. Although the request refers to 2023 Q4, this filing reports annual results; it does not provide a clear standalone fourth-quarter income statement or cash-flow comparison.
Business context
United-Guardian manufactures and sells cosmetic ingredients, pharmaceuticals, medical lubricants and, beginning in 2024, sexual-wellness ingredients. It operates as one business segment. The company discontinued its low-volume industrial product line after Q2 2023. Lubrajel and Renacidin together represented approximately 94% of FY2023 sales, increasing from 92% in FY2022.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $10.89 million | $12.70 million |
| Gross profit / margin | $5.41 million / 49.7% | $6.70 million / 52.8% |
| Operating income / margin | $2.86 million / 26.3% | $4.04 million / 31.8% |
| Net income | $2.58 million | $2.57 million |
| Basic and diluted EPS | $0.56 | $0.56 |
| Cash from operations | $3.14 million | $2.53 million |
| Cash and cash equivalents at year-end | $8.24 million | $0.83 million |
| Marketable securities at year-end | $0.85 million | $5.65 million |
Sales declined 14.3%. Gross margin fell as lower-margin pharmaceuticals became a larger share of sales and reduced production increased per-unit overhead. Net income was nearly flat despite lower operating income, in part because investment results swung from a $1.05 million securities loss in 2022 to an $81,095 gain in 2023; investment income rose to $306,651 from $236,695.
Operating cash flow increased mainly from lower inventory and higher accounts payable. Year-end working capital was $10.72 million, up from $8.60 million; the current ratio was 8.0 versus 7.3. The balance sheet reports no long-term debt. Management considers working capital sufficient for the next fiscal year. Capital expenditures were $165,716; a sprinkler-system project had about $69,000 of additional spending planned for the first half of 2024.
Material changes versus FY2022
- Cosmetic-ingredient sales declined approximately 20%, to $4.13 million. Sales to largest distributor Ashland Specialty Ingredients (ASI) fell 19%; the company cited weaker China demand, lower-priced competition, customer destocking and changed ordering patterns.
- Medical-lubricant sales declined 29%, to $1.75 million, primarily reflecting a Chinese contract manufacturer customer working through inventory accumulated in 2022.
- Pharmaceutical net sales were nearly unchanged at $4.95 million. Gross sales of Renacidin and Clorpactin together declined less than 1%.
- Operating expenses fell approximately 4% to $2.08 million, and R&D expenses fell approximately 5% to $464,000.
- Cash dividends paid fell to $459,387 ($0.10 per share) from $3.12 million ($0.68 per share). The board said it expects to consider semiannual dividends. A $0.25-per-share dividend declared in January 2024 was paid in February.
Outlook, risks and unusual items
- Management expects modest increases in operating and R&D expenses in 2024 to support growth initiatives; R&D spending may also depend on required capital investment. The company hopes to begin sales of its new Natrajel sexual-wellness ingredients in 2024, but had no such sales in 2023.
- The ASI distribution agreement ended December 31, 2023, and a replacement agreement had not been finalized when the filing was prepared. Management expected execution by the end of Q2 2024, without assurance. ASI represented approximately 30% of total sales in 2023. The company said ASI continued to fill orders during negotiations.
- Renacidin production was disrupted at its contract manufacturer in October 2023; validation was completed and production restarted by February 12, 2024. Separately, a Renacidin packaging supplier temporarily stopped production in Q4 for maintenance and to address FDA observations; it expected to fill outstanding orders in early March 2024. Renacidin relies on an outside manufacturer.
- Four wholesalers and distributors accounted for approximately 77% of gross sales and 89% of year-end receivables in 2023. Three raw-material vendors represented approximately 83% of raw-material purchases. The filing notes that disruption at the Renacidin manufacturer or significant customers could materially affect results.
- Management reported no raw-material delivery delays or increased shipping costs to date from Red Sea/Suez-related supply instability, but warned that longer lead times or higher costs could pressure future margins.
- A new Medicare Part D manufacturer discount program begins in 2025 and could increase rebates. CMS notified the company in January 2024 that it qualified as a specified small manufacturer, providing a phase-in of discounts; the ultimate financial effect remains uncertain.
- The company changed auditors in August 2023, dismissing Baker Tilly and retaining Grassi. The filing reports no disagreements or reportable events with the former auditor. Both audit opinions were unqualified, and the current auditor reported no critical audit matters.
- Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not provide an internal-control attestation. No material legal proceedings were reported.
Important facts for investors to verify
- Whether a new ASI distribution agreement was executed, on what terms, and whether distribution and sales remained uninterrupted.
- Whether Renacidin packaging and contract-manufacturing supply normalized, and whether any delayed orders or customer effects followed.
- Progress in Natrajel commercialization and actual 2024 customer orders, given the absence of 2023 sales.
- Whether cosmetic demand, particularly in China, and medical-lubricant customer inventory levels recovered; monitor pricing pressure and gross margin.
- The impact of 2025 Medicare Part D discounts after the specified-small-manufacturer phase-in, as well as customer and supplier concentration.
- Dividend decisions and capital needs, including planned sprinkler-system spending and any investment required for growth.